amiodarone has been researched along with benzbromarone in 15 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (6.67) | 18.2507 |
2000's | 4 (26.67) | 29.6817 |
2010's | 10 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
Gumieniczek, A; Przyborowski, L | 1 |
Gasser, R; Hänni, A; Kaufmann, P; Krähenbühl, S; Roberts, P; Török, M | 1 |
McGinnity, DF; Riley, RJ; Trigg, S; Tucker, J | 1 |
Kumar, V; Locuson, CW; Sham, YY; Tracy, TS | 1 |
Aslamkhan, AG; Gonzalez, R; Imredy, J; Kaczor, A; Kuhls, M; Lebron, J; Liaw, A; Liu, L; Mitra, K; Pearson, K; Ruth, M; Sistare, FD; Vu, H; Wei, C; Xu, Q; Yu, Y | 1 |
1 review(s) available for amiodarone and benzbromarone
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
14 other study(ies) available for amiodarone and benzbromarone
Article | Year |
---|---|
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Thin-layer chromatographic analysis of some benzofuran derivatives in human plasma.
Topics: Amiodarone; Benzbromarone; Benzofurans; Chromatography, Thin Layer; Fibrinolytic Agents; Humans; Uricosuric Agents; Vasodilator Agents | 1994 |
Mechanisms of benzarone and benzbromarone-induced hepatic toxicity.
Topics: Amiodarone; Animals; Apoptosis; Benzbromarone; Benzofurans; Cell Line, Tumor; Hepatocytes; Ketone Bodies; Liver; Male; Membrane Potentials; Mitochondria, Liver; Mitochondrial Swelling; Molecular Structure; Necrosis; Oxidation-Reduction; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species | 2005 |
Prediction of CYP2C9-mediated drug-drug interactions: a comparison using data from recombinant enzymes and human hepatocytes.
Topics: Amiodarone; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzbromarone; Cytochrome P-450 CYP2C9; Diclofenac; Drug Interactions; Enzyme Inhibitors; Hepatocytes; Humans; In Vitro Techniques; Kinetics; Naproxen; Recombinant Proteins; Reproducibility of Results | 2005 |
Amiodarone analog-dependent effects on CYP2C9-mediated metabolism and kinetic profiles.
Topics: Amiodarone; Aryl Hydrocarbon Hydroxylases; Benzbromarone; Cytochrome P-450 CYP2C9; Dose-Response Relationship, Drug; Enzyme Inhibitors; Genotype; Isoenzymes; Kinetics; Methylation; Molecular Structure; Naproxen; Phosphatidylcholines; Protein Binding; Quantitative Structure-Activity Relationship; Substrate Specificity | 2006 |
Can Galactose Be Converted to Glucose in HepG2 Cells? Improving the
Topics: Amiodarone; Benzbromarone; Chemical and Drug Induced Liver Injury; Galactose; Glucose; Hep G2 Cells; Humans; Metabolomics; Mitochondria, Liver; Piperazines; Triazoles; Troglitazone; Tumor Cells, Cultured | 2019 |